for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arbutus Biopharma Corp

ABUS.OQ

Latest Trade

2.09USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.82

 - 

3.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Arbutus Reports First Quarter 2020 Financial Results

May 11 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES PIPELINE UPDATE AND ANNOUNCES NEW RESEARCH INITIATIVE TO IDENTIFY NOVEL ANTIVIRAL THERAPIES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS.Q1 LOSS PER SHARE $0.25.Q1 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.ON TRACK TO HAVE ADDITIONAL RESULTS FROM WEEK 12 PORTION OF 60 MG SINGLE-DOSE COHORT IN Q2.ESTABLISHMENT OF COVID-19 EFFORT DOES NOT IMPACT ARBUTUS' CURRENT CASH BURN GUIDANCE FOR 2020 OF $54 TO $58 MILLION.

Arbutus Announces Positive Preliminary Phase 1A/1B Clinical Trial Results For AB-729

March 26 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS ANNOUNCES POSITIVE PRELIMINARY PHASE 1A/1B CLINICAL TRIAL RESULTS FOR AB-729, A PROPRIETARY GALNAC DELIVERED RNAI COMPOUND IN DEVELOPMENT FOR PEOPLE LIVING WITH CHRONIC HEPATITIS B.ARBUTUS BIOPHARMA CORP - POSITIVE SINGLE DOSE AB-729 DATA IN CHRONIC HEPATITIS B SUBJECTS SUPPORTS FURTHER CLINICAL DEVELOPMENT.

Arbutus Biopharma Reports Q4 Loss Per Share Of $2.89

March 5 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS, CONFIRMS 2020 CORPORATE OBJECTIVES AND PROVIDES PIPELINE UPDATE.Q4 LOSS PER SHARE $2.89.Q4 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.ARBUTUS BIOPHARMA - ENDED YEAR WITH $90.8 MILLION IN CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS, IS SUFFICIENT TO FUND OPERATIONS INTO MID-2021.ARBUTUS BIOPHARMA - EXPECTS TO UTILIZE BETWEEN $54 TO $58 MILLION OF CASH & INVESTMENTS TO FUND OPERATIONS IN 2020.

Arbutus Biopharma Expects To Utilize Between $54 To $58 Million Of Cash & Investments To Fund Operations In 2020

March 5 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS BIOPHARMA - 2019 LOSS PER SHARE $2.89.ARBUTUS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS, CONFIRMS 2020 CORPORATE OBJECTIVES AND PROVIDES PIPELINE UPDATE.Q4 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.ARBUTUS BIOPHARMA - ENDED YEAR WITH $90.8 MILLION IN CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS, IS SUFFICIENT TO FUND OPERATIONS INTO MID-2021.ARBUTUS BIOPHARMA - EXPECTS TO UTILIZE BETWEEN $54 TO $58 MILLION OF CASH & INVESTMENTS TO FUND OPERATIONS IN 2020.

Arbutus To Discontinue AB-452 And Pursue Development Of Next Generation Oral HBV RNA-destabilizer

Feb 10 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS ANNOUNCES DECISION TO DISCONTINUE AB-452 AND TO PURSUE DEVELOPMENT OF A NEXT GENERATION HBV SPECIFIC ORAL RNA-DESTABILIZER.ARBUTUS BIOPHARMA CORP - ARBUTUS EXPECTS TO ANNOUNCE AB-729 PRELIMINARY PHASE 1A/1B DATA LATE Q12020.ARBUTUS BIOPHARMA CORP - CONTINUE RESEARCH AND DEVELOPMENT OF A NEXT GENERATION ORAL HBV RNA-DESTABILIZER.ARBUTUS BIOPHARMA CORP - REITERATED ITS EARLIER GUIDANCE FOR BOTH AB-729 AND AB-836.ARBUTUS BIOPHARMA - FOR AB-836, ARBUTUS' NEXT GENERATION CAPSID INHIBITOR, EXPECTS TO COMPLETE INVESTIGATIONAL NEW DRUG ENABLING STUDIES BY YEAR END.ARBUTUS BIOPHARMA CORP - LOOK FORWARD TO ANNOUNCING OUR PRELIMINARY SAFETY AND EFFICACY DATA FOR AB-729 LATER THIS QUARTER.

Arbutus Biopharma Files For Mixed Shelf Of Upto $150 Mln

Dec 23 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS BIOPHARMA CORP FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

Foresite Capital Fund Reports Passive Stake In Arbutus Biopharma

Dec 9 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::FORESITE CAPITAL FUND IV, L.P. REPORTS 5.6% PASSIVE STAKE IN ARBUTUS BIOPHARMA AS OF DEC 2, 2019 - SEC FILING.

Arbutus Reports Third Quarter 2019 Financial Results

Nov 6 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $1.50.Q3 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.QTRLY REVENUE $3.1 MILLION VERSUS$1.6 MILLION.HAD APPROXIMATELY $90.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2019.BELIEVES ITS EXISTING CASH AND CASH EQUIVALENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO EARLY 2021.DISCONTINUATION OF AB-506 DEVELOPMENT PROGRAM IS ANTICIPATED TO REDUCE CASH BURN IN SHORT TERM.

Arbutus Biopharma Q2 Loss Per Share $0.46

Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.SAYS RECEIVED $20 MILLION IN GROSS PROCEEDS FROM SALE OF A PORTION OF ONPATTRO ROYALTY ENTITLEMENT.CO BELIEVES ITS CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO SECOND HALF OF 2020.ANTICIPATE MOVING INTO A COMBINATION PROOF-OF-CONCEPT PHASE 2 CLINICAL TRIAL IN SUBJECTS WITH CHRONIC HEPATITIS B IN H2 2020.

Veritas Reaches A Mutual Settlement With Arbutus Biopharma Corporation

July 23 (Reuters) - Veritas Pharma Inc <VRT.CD>::VERITAS REACHES A MUTUAL SETTLEMENT WITH ARBUTUS BIOPHARMA CORPORATION.VERITAS PHARMA INC - HAS ENTERED INTO A CONFIDENTIAL SETTLEMENT THAT WILL RESOLVE THE ARBUTUS BIOPHARMA LITIGATION COMPLETELY.VERITAS PHARMA - REACHED SETTLEMENT WITH ARBUTUS BIOPHARMA REGARDING LITIGATION COMMENCED BY ARBUTUS FOR CLAIMS RELATED TO A COMMERCIAL LEASE SPACE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up